Living With Pulmonary Fibrosis Means a Life of Contrasts

I have always been passionate about professional development and am often the first to express interest in training sessions, conferences, or webinars to enhance my learning in the field of psychotherapy. Professional development stretches my thinking and introduces concepts I may not have thought about. I recently attended a virtual…

A change in seasons is underway here in Virginia, and across the mid-Atlantic. Trees that were once lush and green are now exploding with fiery red, burnt orange, and golden hues. All of those leaves have also begun to fall from the trees to the ground. Firewood is stacked and…

Boehringer Ingelheim has enrolled the first patient in FIBRONEER-IPF, a Phase 3 clinical trial evaluating the efficacy, safety, and tolerability of BI 1015550, an investigational therapy for people with idiopathic pulmonary fibrosis (IPF). The trial is part of the FIBRONEER global program, which also includes FIBRONEER-ILD, a similar Phase…

AbbVie’s portfolio of antibodies for the potential treatment of idiopathic pulmonary fibrosis (IPF) now includes DJS-002 — a first-in-class antibody directed against lysophosphatidic acid receptor-1 (LPAR1), a protein thought to drive the progression of IPF and other fibrotic diseases. This was made possible by AbbVie’s estimated $250 million acquisition of…

When I was diagnosed with idiopathic pulmonary fibrosis (IPF) in January 2017, it felt like my entire world had shrunk. My wife and caregiver, Susan, and I were suddenly alone on an island. I’m confident many feel this way after receiving a diagnosis. However, a rare, incurable disease can…

I have begun a new, educational phase in my life: I’m working to become a patient advocate. Honestly, I’d never thought about patient advocacy until I was diagnosed with pulmonary fibrosis in December 2019. But it became extremely important to me when I realized that my…

A test by Veracyte can be used to predict which patients with interstitial lung diseases (ILDs), including idiopathic pulmonary fibrosis (IPF), are more likely to experience progressive decline in their lung function, according to new data. Called the Envisia Genomic Classifier, the test works by identifying the genomic…

Greetings from Griefville. This column comes in three parts. Part 1: Grief is the worst Five years ago, I lost my cousin Charlie to lung cancer. He went to the emergency room with what he thought was pneumonia, and six weeks later, he was gone. It was a cold, dark…

The benefits of mindfulness are becoming more prevalent in literature. A quick search on social media or Google will reveal not only the importance of practicing mindfulness regularly, but also an abundance of self-led practice videos and articles about the topic. However, I wish the benefits of mindfulness for those…

The cellular aging of a group of cells called alveolar type 2 pneumocytes — which work to promote airway stability, and play a key role in lung repair after injury — may be responsible for driving pulmonary fibrosis (PF). That’s according to new findings from a team led by…